Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04692103
Recruitment Status : Not yet recruiting
First Posted : December 31, 2020
Last Update Posted : March 3, 2021
Sponsor:
Information provided by (Responsible Party):
University of Washington

Tracking Information
First Submitted Date  ICMJE December 30, 2020
First Posted Date  ICMJE December 31, 2020
Last Update Posted Date March 3, 2021
Estimated Study Start Date  ICMJE April 1, 2021
Estimated Primary Completion Date April 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 30, 2020)
  • Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV), assessed by a one-sample test of the percent Change in FES SUV [ Time Frame: From time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 1-12 weeks) ]
    FES uptake will be quantified using lean body mass adjusted SUV (SULmean). The geometric mean will be calculated for up to 3 lesions per patient. Systematic change in FES SULgmean between baseline and a second FES scan measured using a sign test where the median change is zero.
  • F-18 16 alpha-fluoroestradiol (FES) uptake [ Time Frame: From time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 1-12 weeks) ]
    Quantitative measures of FES uptake for each disease site will be determined by drawing regions-of-interest on lesions to determine maximal FES uptake (SUVmax) per lesion. Up to 10 sites seen on the static torso survey will be quantified. Lesions will be qualitatively determined to be visible or not visible.
  • Proportion of patients with a threshold of percentage change, or that surpass a targeted follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV) [ Time Frame: From time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 1-12 weeks) ]
    The number of patients showing a 20% increase in FES uptake (SULgmean or SUVmax) compared to baseline from the first to second or third scan using a 90% Wilson score binomial confidence interval.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 30, 2020)
Time to Disease Progression [ Time Frame: From start of therapy up to 20 years ]
Time to disease progression will be measured as the time from the start of endocrine therapy to the time the patient is first recorded as having disease progression.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
Official Title  ICMJE Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-targeted Therapy
Brief Summary This clinical trial studies use of F-18 16 alpha-fluoroestradiol ([F-18] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.
Detailed Description

OUTLINE:

Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.

After completion of study, patients are followed up for up to 20 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Condition  ICMJE
  • Estrogen Receptor Positive
  • Primary or Recurrent Breast Carcinoma
  • Stage IV Breast Cancer AJCC v6 and v7
Intervention  ICMJE
  • Drug: F-18 16 Alpha-Fluoroestradiol
    Undergo F-18 FES PET/CT
    Other Names:
    • F-18 FES
    • FES
    • Fluorine-18 16 alpha-fluoroestradiol
    • Fluoroestradiol F-18
  • Procedure: Positron Emission Tomography
    Undergo F-18 FES PET/CT
    Other Names:
    • Medical Imaging
    • PET Scan
    • Positron Emission Tomography Scan
    • Positron-Emission Tomography
  • Procedure: Computed Tomography
    Undergo F-18 FES PET/CT
    Other Names:
    • CAT Scan
    • Computerized Axial Tomography
    • CT scan
  • Drug: Fludeoxyglucose F-18
    Undergo FDG PET/CT
    Other Names:
    • FDG
    • Fluorodeoxyglucose F18
    • 18FDG
  • Procedure: Positron Emission Tomography
    Undergo FDG PET/CT
    Other Names:
    • Medical Imaging
    • PET
    • PET Scan
  • Procedure: Computed Tomography
    Undergo FDG PET/CT
    Other Name: CAT Scan
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Study Arms  ICMJE Experimental: Diagnostic (F-18 FES PET/CT)
Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
Interventions:
  • Drug: F-18 16 Alpha-Fluoroestradiol
  • Procedure: Positron Emission Tomography
  • Procedure: Computed Tomography
  • Drug: Fludeoxyglucose F-18
  • Procedure: Positron Emission Tomography
  • Procedure: Computed Tomography
  • Other: Laboratory Biomarker Analysis
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: December 30, 2020)
20
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 30, 2041
Estimated Primary Completion Date April 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancer
  • Breast cancer from ER+ primary that is seen on other imaging tests. Tumor ER expression must have been confirmed by immunohistocytochemistry of primary tumor or recurrent disease.
  • At least one site of disease 1.5 cm or greater is needed to meet the spatial resolution limits of PET imaging.
  • Patients must have been off tamoxifen or other estrogen receptor blocking agents for at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES.
  • Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist. Selected treatments may be part of experimental treatment protocols for which the patient would be separately consented.
  • Patients must be willing to undergo serial imaging procedures.
  • Patients must agree to allow access to clinical records regarding response to treatment and long term follow up.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • An inability to lie still for the tests
  • Individuals weighing more than 300 lb. (this is the weight limit of the scanner table)
  • Pregnant or lactating. Women of childbearing potential with either a positive or no pregnancy test at baseline are excluded.
  • Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or clinically significant cardiac disease - congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication).
  • Use of tamoxifen, faslodex, DES or any other ER blocking agent < 6 weeks or chemotherapy < 3 weeks prior to imaging scan.
  • Uncontrolled diabetes mellitus (fasting glucose > 200 mg/dL)
  • Adult patients who require monitored anesthesia for PET scanning.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Hannah Linden 206 606-6710 hmlinden@uw.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04692103
Other Study ID Numbers  ICMJE RG1007834
10465 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party University of Washington
Study Sponsor  ICMJE University of Washington
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Hannah Linden Fred Hutch/University of Washington Cancer Consortium
PRS Account University of Washington
Verification Date December 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP